Tag Archive for: liver cirrhosis

Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis

/in

Results support progression of EMERALD clinical trial of Resolution’s engineered macrophage therapy, RTX001 Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in the journal Cell Stem Cell Resolution is pioneering engineered Regenerative Macrophage Therapy – which uses engineered macrophages designed to deliver a more […]

Read more

Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025

/in

New clinical data from the MATCH Phase II study shows early improvement in liver function after treatment with non-engineered macrophages is associated with positive long term clinical outcomes New preclinical data from Resolution’s first engineered Regenerative Macrophage Therapy, RTX001, shows significant reduction of systemic inflammation Comes as Resolution progresses its Phase I/II EMERALD study of […]

Read more

Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease

/in

RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events Enrolment is now open for the study, with initial data readout expected in 2026 Edinburgh and London, UK, 3 September 2025 – Resolution Therapeutics (“Resolution” or “Company”), a […]

Read more

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

/in

– Proprietary manufacturing process enables robust and scalable GMP-compliant manufacture of autologous engineered RMT products, including lead asset RTX001 in end-stage liver disease (ESLD). – Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo. – The EMERALD Phase1/2 interventional study […]

Read more

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

/in

Edinburgh and London, UK, 10 December 2024 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company focused on pioneering regenerative macrophage therapy (“RMT”) in inflammatory and fibrotic diseases,  today announces it has presented a poster at the Keystone Symposia Fibrosis: Inflammation, Drivers, and Therapeutic Resolution taking place on 8 – 11 December 2024 in […]

Read more
© Optimum Strategic Communications.